Case Control Study
Copyright ©The Author(s) 2024.
World J Gastrointest Surg. May 27, 2024; 16(5): 1259-1270
Published online May 27, 2024. doi: 10.4240/wjgs.v16.i5.1259
Table 1 The baseline characteristics of patients before and after propensity-score-matching, n (%)
FactorsBefore PSM
After PSM
Non-IFD (n = 976)
IFD (n = 97)
χ²
P value
Non-IFD (n = 194)
IFD (n = 97)
    χ²
P value
Gender6.8310.0090.0001.000
    Female426 (43.6)29 (29.9)58 (29.9)29 (29.9)
    Male550 (56.4)68 (70.1)136 (70.1)68 (70.1)
Tumor locations8.1310.0430.0001.000
    Asending colon402 (41.2)51 (52.6)102 (52.6)51 (52.6)
    Transverse colon63 (6.5)7 (7.2)14 (7.2)7 (7.2)
    Descending colon395 (40.5)25 (25.8)50 (25.8)25 (25.8)
    Sigmoid colon 116 (11.8)14 (14.4)28 (14.4)14 (14.4)
Age (yr)2.0600.1510.0630.801
    < 65499 (51.1)57 (58.7)111 (57.2)57 (58.7)
    ≥ 65477 (48.9)40 (41.3)83 (42.8)40 (41.3)
ASA grade1.3360.2480.2480.619
    I-II888 (84.2)86 (88.7)168 (86.6)86 (88.7)
    III-IV154 (15.8)11 (11.3)26 (13.4)11 (11.3)
CEA1.2120.2711.4570.227
    < 5 ng/mL715 (73.3)66 (68.1)145 (77.7)66 (68.1)
    ≥ 5 ng/mL261 (26.7)31 (31.9)49 (22.3)31 (31.9)
CA19-90.0390.8441.1550.282
    < 34 U/mL852 (87.3)84 (86.6)176 (90.8)84 (86.6)
    ≥ 34 U/mL124 (22.7)13 (13.5)18 (9.2)13 (13.5)
Hypertension (yes)316 (32.4)33 (34.0)1.1090.74263 (32.5)33 (34.0)0.0700.791
DM (yes)198 (19.9)18 (18.6)0.0980.75526 (13.4)18 (18.6)1.3390.247
CHD (yes)98 (10.0)10 (10.3)0.0070.93310 (5.2)10 (10.3)2.6850.101
Antiplatelet (yes)89 (9.1)9 (9.3)0.0030.95610 (5.2)9 (9.3)1.8020.179
Abdominal surgery (yes)99 (10.1)12 (12.4)0.4770.49033 (17.1)12 (12.4)1.0650.302